1. Home
  2. PEBO vs DMAC Comparison

PEBO vs DMAC Comparison

Compare PEBO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp Inc.

PEBO

Peoples Bancorp Inc.

HOLD

Current Price

$31.62

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.81

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBO
DMAC
Founded
1902
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
457.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PEBO
DMAC
Price
$31.62
$8.81
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$34.58
$15.50
AVG Volume (30 Days)
156.5K
581.8K
Earning Date
01-20-2026
11-12-2025
Dividend Yield
5.22%
N/A
EPS Growth
N/A
N/A
EPS
2.86
N/A
Revenue
$555,347,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
$10.99
N/A
Revenue Growth
10.92
N/A
52 Week Low
$26.21
$3.19
52 Week High
$35.12
$10.42

Technical Indicators

Market Signals
Indicator
PEBO
DMAC
Relative Strength Index (RSI) 69.60 57.59
Support Level $30.14 $8.40
Resistance Level $31.53 $10.14
Average True Range (ATR) 0.47 0.70
MACD 0.18 -0.01
Stochastic Oscillator 90.42 35.91

Price Performance

Historical Comparison
PEBO
DMAC

About PEBO Peoples Bancorp Inc.

Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: